Eton Pharmaceuticals (ETON) Corporate Presentation summary

Vision and strategy

• Aims to be a leader in ultra-rare diseases, focusing on patient access and innovative therapies.

• Growth strategy centers on organic product growth, internal pipeline development, and external acquisitions.

• Maintains strong partnerships with advocacy groups and healthcare professionals to enhance patient support and education.

Portfolio and pipeline

• Built a broad portfolio with 8 commercial products and 5 pipeline programs targeting pediatric endocrinology and metabolic disorders.

• Recent acquisitions include INCRELEX and GALZIN, with new pipeline assets Amglidia, ET-700, and ET-800 added.

• Pipeline includes late-stage programs such as ET-700 (Wilson disease), ET-800 (endocrinology), and Zeneo (adrenal crisis autoinjector).

Commercial performance and outlook

• Product revenue grew from $3M in 2021 to $39M in 2024, with a clear path to $100M+ near-term revenue.

• 17 consecutive quarters of sequential revenue growth, driven by key products like ALKINDI SPRINKLE and Carglumic Acid.

• Expects to exit 2025 at an $80M revenue run rate, with major contributions from INCRELEX, GALZIN, and KHINDIVI.